<DOC>
	<DOCNO>NCT02841228</DOCNO>
	<brief_summary>Lung cancer one common cancer lead cause cancer death worldwide . Approximately 80 % NSCLC inoperable . The prognosis patient LA-NSCLC remains disappointing . Investigators hypothesize use simultaneous integrate boost intensity modulate radiotherapy ( SIB-IMRT ) technology safety increase radiation dose benefit inoperable NSCLC patient .</brief_summary>
	<brief_title>Intensity-modulated Radiotherapy ( IMRT ) With Simultaneous Integrated Boost ( SIB ) Inoperable Non-small-cell Lung Cancer</brief_title>
	<detailed_description>Lung cancer one common cancer lead cause cancer death patient worldwide . Approximately 80 % NSCLC inoperable . Concurrent chemo-radiation therapy ( CCRT ) standard treatment locally advance NSCLC candidate surgery . Nevertheless , prognosis patient locally advanced NSCLC ( LA-NSCLC ) still poor . Local control ( LC ) CCRT one important prognostic factor . Local failure common standard-dose chemoradiation NSCLC . Studies stereotactic body radiation therapy ( SBRT ) show steep dose response treat early-stage lung cancer . Improving total dose shorten overall treatment time may effective improve LC rate . However , problem remain due toxicity adjacent critical structure ( e.g , lung , heart , esophagus ) , target volume usually limit dos escalate safely deliver conventional radiotherapy technique . In order avoid acute late radiation toxicity normal tissue , different dose prescription deliver different target volume fraction , deliver high dose Gross Tumor Volume ( GTV ) relatively low dose subclinical disease . The technique call simultaneous integrate boost intensity modulate radiotherapy ( SIB-IMRT ) . Investigators hypothesize use SIB-IMRT technology safety increase radiation dose benefit inoperable NSCLC patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologically confirm NSCLC , inoperable stage IIAIIIB , accord American Joint Committee Cancer （AJCC）Cancer Stage 7th 2 . Performance status 0 2 , ≤5 % weight loss within past 6 month 3 . A forced expiratory volume 1 second ≥ 1 L 4 . Life expectancy &gt; 3 month 5 . No invasion large vessel , heart , esophagus , spinal cord . 6 . Based conformal treatment planning , volume lung exceed 20 Gy ( V20 ) must been≤30 % , mean esophagus dose≤34 Gy , volume esophagus exceed 55 Gy ( V55 ) ≤30 % 7 . Tolerable agree IntensityModulated Radiation Therapy（IMRT） concurrent chemoradiotherapy 8 . Without severe disease 9 . Informed consent 1 . Had receive prior thoracic radiotherapy 2 . Supraclavicular lymph node metastasis , pleural pericardial effusion , superior vena cava syndrome 3 . Pregnant lactate woman 4 . Serious complication 5 . Other primary malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>SIB-IMRT</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Radiochemothearpy</keyword>
</DOC>